Diosmin
Diosmin is a small molecule pharmaceutical. It is currently being investigated in clinical studies.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
46 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Venous insufficiency | D014689 | — | — | 4 | 1 | — | 5 | ||
| Periodontal diseases | D010510 | K05.6 | — | — | — | 1 | — | 1 | |
| Pharmacokinetics | D010599 | — | — | — | 1 | — | 1 | ||
| Venous thrombosis | D020246 | HP_0004936 | I82.40 | — | — | — | 1 | — | 1 |
| Postthrombotic syndrome | D054070 | EFO_0007452 | I87.0 | — | — | — | 1 | — | 1 |
| Chronic periodontitis | D055113 | EFO_0006343 | K05.3 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hemorrhoids | D006484 | EFO_0009552 | K64 | — | — | 1 | — | 2 | 3 |
| Osteoporosis | D010024 | EFO_0003882 | M81.0 | — | 1 | 1 | — | — | 2 |
| Infertility | D007246 | EFO_0000545 | — | 1 | 1 | — | — | 1 | |
| Cerebrospinal fluid leak | D065634 | G96.0 | — | — | 1 | — | — | 1 | |
| Syndrome | D013577 | — | — | 1 | — | — | 1 | ||
| Drug-related side effects and adverse reactions | D064420 | T88.7 | — | — | 1 | — | — | 1 | |
| Ulcerative colitis | D003093 | EFO_0000729 | K51 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Metabolic syndrome | D024821 | EFO_0000195 | E88.81 | — | 2 | — | — | 2 | 4 |
| Obesity | D009765 | EFO_0001073 | E66.9 | — | 2 | — | — | — | 2 |
| Pathologic processes | D010335 | — | 1 | — | — | — | 1 | ||
| Insulin resistance | D007333 | EFO_0002614 | — | 1 | — | — | — | 1 | |
| Menorrhagia | D008595 | N92.0 | 1 | 1 | — | — | — | 1 | |
| Covid-19 | D000086382 | U07.1 | — | 1 | — | — | — | 1 | |
| Pain | D010146 | EFO_0003843 | R52 | — | 1 | — | — | — | 1 |
| Vomiting | D014839 | HP_0002013 | R11.1 | — | 1 | — | — | — | 1 |
| Nausea | D009325 | HP_0002018 | R11.0 | — | 1 | — | — | — | 1 |
| Headache | D006261 | HP_0002315 | R51 | — | 1 | — | — | — | 1 |
Show 13 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Coronavirus infections | D018352 | EFO_0007224 | B34.2 | 1 | — | — | — | — | 1 |
| Therapeutic equivalency | D013810 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Alcoholic fatty liver | D005235 | K70.0 | — | — | — | — | 3 | 3 | |
| Body weight changes | D001836 | — | — | — | — | 2 | 2 | ||
| Healthy volunteers/patients | — | — | — | — | — | 1 | 1 | ||
| Inflammation | D007249 | — | — | — | — | 1 | 1 | ||
| Hypoxia | D000860 | R09.02 | — | — | — | — | 1 | 1 | |
| Acid-base imbalance | D000137 | — | — | — | — | 1 | 1 | ||
| Psychological power | D011209 | — | — | — | — | 1 | 1 | ||
| Oxidative stress | D018384 | EFO_1001905 | — | — | — | — | 1 | 1 | |
| Postmenopausal osteoporosis | D015663 | EFO_0003854 | — | — | — | — | 1 | 1 | |
| Hypertension | D006973 | EFO_0000537 | I10 | — | — | — | — | 1 | 1 |
Show 4 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | DIOSMIN |
| INN | diosmin |
| Description | Diosmin is a disaccharide derivative that consists of diosmetin substituted by a 6-O-(alpha-L-rhamnopyranosyl)-beta-D-glucopyranosyl moiety at position 7 via a glycosidic linkage. It has a role as an antioxidant and an anti-inflammatory agent. It is a glycosyloxyflavone, a rutinoside, a disaccharide derivative, a monomethoxyflavone and a dihydroxyflavanone. It is functionally related to a diosmetin. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | COc1ccc(-c2cc(=O)c3c(O)cc(O[C@@H]4O[C@H](CO[C@@H]5O[C@@H](C)[C@H](O)[C@@H](O)[C@H]5O)[C@@H](O)[C@H](O)[C@H]4O)cc3o2)cc1O |
Identifiers
| PDB | — |
| CAS-ID | 520-27-4 |
| RxCUI | 3489 |
| ChEMBL ID | CHEMBL231884 |
| ChEBI ID | 4631 |
| PubChem CID | 5281613 |
| DrugBank | DB08995 |
| UNII ID | 7QM776WJ5N (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,884 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
310 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more